In a latest move the Public Citizen Group has sued US Federal Agency, The Food and Drug Administration (FDA) for its failure to act lawfully in withdrawing and recalling the highest dose of an Alzheimer’s disease drug Aricept from the market. The lawsuit was filed in federal court in Washington.

The petition that was submitted by the Public Citizen Group has categorically asked the removal of 23-mg dose of Aricept as it possess serious threats and side-effects to human body. The agency has requested the court to halt sales of Aricept that comes in a higher dose of 23-milligram without any delay so as to save the life of millions of Americans who have been consuming it.

It is noteworthy that Aricept is one of the most prevalent drugs that are available in the United States to treat the condition of Alzheimer in people of all ages. The drug is manufactured and marketed by one of the pharmaceutical giants Japan’s Eisai Co. Ltd. While addressing the newspersons and pertaining people Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group, said around 350,000 prescriptions have been filled in the United States for Aricept 23 and hence it was important for the FDA to act lawfully and that too in a specified amount of time. The Director also added that “Allowing Eisai to exploit and harm vulnerable patients with Alzheimer’s disease is unconscionable,” and that people have every right to oppose and react to such incidence.

Moving on the same line he added “By ignoring Public Citizen’s petition for more than a year, the agency has ignored (its) responsibility,” which is not a favorable condition for the welfare of the country.

The charges framed by the Public Citizen Group also accuses FDA of not acting seriously and responsively and that the FDA required the company to prove in a study that the high dose improved patients’ prevailing condition, however no study have ever been conducted by the company to support it statistically. No statistical data was published to prove that the higher dose of Aricept could benefit people in improving their physical and mental condition.

It is noteworthy to know that while investigating the high dose of the Aricept FDA’s own examiners and reviewers underlined that 23 milligram dose of Aricept doesn’t work better at controlling symptoms of moderate-to-severe Alzheimer’s than two low doses. On the contrary to the prevailing perception the high dose of Aricept poses a more serious threat and could have many side-effects including pneumonia, vomiting, gastrointestinal bleeding, esophageal rupture. Asides these some other complications and side-effects that the drug pose to people are diarrhea, nausea, confusion and anorexia.